Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 11,793 shares, a decline of 97.2% from the April 30th total of 423,802 shares. Based on an average daily volume of 637,751 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Chugai Pharmaceutical Stock Up 3.0%

OTCMKTS:CHGCY traded up $0.71 on Wednesday, hitting $24.63. The stock had a trading volume of 131,973 shares, compared to its average volume of 231,129. The business’s 50-day simple moving average is $26.51 and its two-hundred day simple moving average is $27.36. The stock has a market cap of $81.07 billion, a price-to-earnings ratio of 27.37 and a beta of 0.63. Chugai Pharmaceutical has a 52-week low of $19.50 and a 52-week high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Friday, April 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. The firm had revenue of $2.05 billion during the quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on CHGCY shares. UBS Group upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.